S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
The 4 highest-shorted large-cap stocks
The top-rated strong-buy stocks on Marketbeat’s radar
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
What’s next for GM stock: Buybacks and a dividend increase
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023

Edwards Lifesciences Stock Price, News & Analysis (NYSE:EW)

$67.43
+0.33 (+0.49%)
(As of 11/29/2023 ET)
Compare
Today's Range
$67.14
$68.31
50-Day Range
$61.72
$73.70
52-Week Range
$60.57
$94.87
Volume
3.14 million shs
Average Volume
4.01 million shs
Market Capitalization
$40.90 billion
P/E Ratio
28.82
Dividend Yield
N/A
Price Target
$82.78

Edwards Lifesciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
22.8% Upside
$82.78 Price Target
Short Interest
Healthy
1.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.53mentions of Edwards Lifesciences in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$12.61 M Sold Last Quarter
Proj. Earnings Growth
11.95%
From $2.51 to $2.81 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

59th out of 949 stocks

Surgical Appliances & Supplies Industry

4th out of 20 stocks


EW stock logo

About Edwards Lifesciences Stock (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

EW Stock Price History

EW Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Edwards Lifesciences (NYSE:EW) Upgraded at StockNews.com
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Edwards Lifesciences Q3: Clinical Trial Updates Impress
Why Edwards Lifesciences Stock Plummeted Today
See More Headlines
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/25/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
1/30/2024

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
17,300
Year Founded
1958

Price Target and Rating

Average Stock Price Target
$82.78
High Stock Price Target
$107.00
Low Stock Price Target
$57.00
Potential Upside/Downside
+22.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
18 Analysts

Profitability

Net Income
$1.52 billion
Pretax Margin
28.11%

Debt

Sales & Book Value

Annual Sales
$5.38 billion
Cash Flow
$2.74 per share
Book Value
$11.09 per share

Miscellaneous

Free Float
598,676,000
Market Cap
$40.90 billion
Optionable
Optionable
Beta
1.02

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














EW Stock Analysis - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price target for 2024?

18 brokers have issued 12-month price targets for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they predict the company's stock price to reach $82.78 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2023?

Edwards Lifesciences' stock was trading at $74.61 at the beginning of 2023. Since then, EW shares have decreased by 9.6% and is now trading at $67.43.
View the best growth stocks for 2023 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 10,750,000 shares, a decline of 6.3% from the October 31st total of 11,470,000 shares. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is presently 2.6 days. Currently, 1.8% of the company's stock are short sold.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, January 30th 2024.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) issued its earnings results on Wednesday, October, 25th. The medical research company reported $0.59 EPS for the quarter, hitting analysts' consensus estimates of $0.59. The medical research company earned $1.48 billion during the quarter, compared to analyst estimates of $1.48 billion. Edwards Lifesciences had a net margin of 24.59% and a trailing twelve-month return on equity of 24.54%. Edwards Lifesciences's revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 EPS.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY23 earnings guidance on Wednesday, October, 25th. The company provided earnings per share (EPS) guidance of $2.50-2.60 for the period, compared to the consensus EPS estimate of $2.55.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (2.90%), Brown Advisory Inc. (2.49%), Morgan Stanley (1.17%), Northern Trust Corp (1.05%), Legal & General Group Plc (0.75%) and Sands Capital Management LLC (0.75%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
This page (NYSE:EW) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -